Advertisement

Topics

Bristol-Myers To Acquire Celgene; To Be Above 40% EPS Accretive In First Year

07:34 EST 3 Jan 2019 | FinanzNachrichten

SUMMIT (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and Celgene Corp. (CELG) announced a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock tra...

Original Article: Bristol-Myers To Acquire Celgene; To Be Above 40% EPS Accretive In First Year

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers To Acquire Celgene; To Be Above 40% EPS Accretive In First Year"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...